Biomakers

| Aspect | Biomakers | Tempus | Foundation Medicine | |--------|-----------|--------|---------------------| | Starting Price | Not publicly posted; sponsored testing may be offered for eligible patients; otherwise quote-based | Not clearly published as a standard list price; offers self-pay discussions via patient support channels | Published self-pay pricing available from the vendor for specific tests in the US | | Best For | LATAM-focused precision oncology ecosystem combining testing, biobank, RWD, and AI components | Large-scale precision oncology diagnostics, multimodal data, and AI; strong US footprint | Widely adopted comprehensive genomic profiling with mature ordering pathways and published financial support | | Key Strength | The vendor states a substantial LATAM precision oncology presence and a focus on underrepresented genomic populations | Scale, product breadth, and established presence in the US oncology market | Transparency on ordering and self-pay pricing; established CDx presence | | Key Weakness | Limited public security/compliance artifacts and limited third-party user reviews; pricing not transparent | Patients sometimes report billing and insurance friction (reported in community forums) | Cost can be high; insurance and payer complexity remain | - Direct competitors and differentiators - Biomakers’ primary stated differentiator is its LATAM presence and network combined with testing, data, and biobank capabilities. - Competitors differentiate via: - Regulatory footprint and companion diagnostic approvals (Foundation Medicine and others) - Very large US-based datasets and AI tooling (Tempus) - Broad payer relationships and established ordering portals (Caris, Foundation) - Pricing comparison - Biomakers pricing is not public, making direct ROI comparisons difficult. - Foundation Medicine publishes self-pay pricing, enabling more straightforward budgeting. - Customer testimonials comparing Biomakers to competitors - Not found in accessible sources. - Market share and adoption trends - Not quantified for Biomakers in accessible independent sources.